Download presentation
Presentation is loading. Please wait.
Published byBrittney West Modified over 5 years ago
1
Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ Of the following frontline options for transplant-ineligible MM, which would you recommend? • Rd until progression Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center
2
Disclosures Consulting: AMGEN, Genzyme, BMS, Otsuka, Celgene, Medtronic, Lilly, Millennium, Binding Site, Onyx, Bayer Speakers Bureaus: None Research: Cylene, Proteolix Patent for FISH based prognostication in MM - about $1500 per year Registered independent Believe in stem cell transplant Dislike wasting your time with this slide
3
IMIDs Thalidomide Lenalidomide Pomalidomide
4
E4A04
5
Blood 2008
6
Blood 2008
8
Cytogenetic Category and Age
9
Cytogenetic Category and Age
Kappor, P Blood 2009 Fonseca, R Br J Haematol 2011
10
Is this unique to myeloma?
CML European studies of imatinib Tamoxifen and breast cancer Lung cancer
11
What not to do when treating the elderly:
Mix lenalidomide & alkylators Use injections Use melphalan Use growth factor Interfere with QOL Use too much steroid Ask patients to drive too much
12
Drive through “Thanks your for shopping at Starbucks. We will have your Rd pills in a second”
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.